Background {#Sec1}
==========

Chronic kidney disease (CKD) is a major complication of diabetes mellitus (DM) occurring in approximately one third of diabetic patients. DM is the leading cause for end-stage renal disease (ESRD) in most countries worldwide \[[@CR1]\]. CKD of all etiologies potentiates cardiovascular disease (CVD) risk, depending on its severity \[[@CR2]\]. The co-incidence of DM and CKD leads to a particularly marked increase in CVD risk \[[@CR3]\]. Given the increasing prevalence of DM, the burden of diabetic kidney disease is expected to further increase in the future \[[@CR4]\].

Good glycaemic control is the mainstay for preventing microvascular complications in patients with DM \[[@CR5], [@CR6]\]. Hemoglobin A1c (HbA1C), which reflects average glycaemic control over the past one to two months, has been shown to better capture increased risk for adverse events than plasma glucose \[[@CR7]\]. Meta-analyses reported an increase of CVD events by approximately 18 % per increase of one percent of HbA1C \[[@CR8]\]. HbA1C targets \<7 % were shown to slow the progression of kidney disease \[[@CR5], [@CR9]\]. Intensive compared to standard glycaemic control also reduced coronary events in type 2 DM in some \[[@CR10]\], albeit not all studies \[[@CR11]\]. On the other hand the risk of severe hypoglycemia is doubled during intensive treatment, especially when the eGFR is \<60 mL/min/1.73 m^2^ \[[@CR12]\].

There are multiple therapeutic options for glycaemic control and they are likely to increase further with the introduction of new oral antidiabetic drugs. However, no clear recommendations exist for antidiabetic therapies in patients with moderately severe CKD and individualized treatment approaches and targets are so far recommended \[[@CR13]\]. Recommendations of regulatory agencies, such as the FDA (Federal Drug Administration) for example for the use of metformin were recently challenged.

Understanding treatment practice and the factors associated with good and poor metabolic control appears important to assess the potential and limitations of different therapeutic regimes and to design future trials comparing different treatment regimes prospectively. Unfortunately, however, data about the use of different glucose-lowering strategies and their combinations in CKD patients are very sparse \[[@CR14], [@CR15]\]. We therefore decided to analyze a large prospective database from German kidney centers \[[@CR16], [@CR17]\], to understand how people with type 2 DM and CKD are currently treated and which factors are associated with metabolic control and with the use of the various classes of antidiabetic drugs.

Methods {#Sec2}
=======

Study population and design {#Sec3}
---------------------------

The German Chronic Kidney Disease (GCKD) study is a prospective observational cohort study of patients with moderately severe CKD. It was approved by local ethics committees and registered in the national registry of clinical studies (DRKS 0003971). 5217 patients aged 18 to 74 years having either an estimated glomerular filtration rate (eGFR) between 30--60 mL/min/1.73 m^2^ (according to the 4-variable MDRD formula \[[@CR18]\]) or proteinuria \>0.5 g/day (or equivalent measures) were enrolled across nine German regional study centres after obtaining written informed consent. All patients are under regular care by nephrologists. Main criteria for exclusion from the GCKD study were non-Caucasian ethnicity, the presence of active malignancy, heart failure stage NYHA IV and any former transplantations. A summary of the baseline data was recently published \[[@CR17]\]. Patients will be prospectively followed for up to 10 years. Details of the study design, enrolment process and study procedures have been reported \[[@CR16]\].

During a structured interview at baseline each patient was asked about concomitant diseases including previous cardiovascular events; medications including antidiabetic drugs and dietary therapy for diabetes were recorded. Drugs were coded according to the Anatomical Therapeutic Chemical (ATC) classification. The treating nephrologists provided the patient's medical history particularly of diabetes, kidney and CV diseases, and kidney biopsy reports.

Definition of diabetes mellitus {#Sec4}
-------------------------------

For study purposes, DM was defined according to ADA criteria \[[@CR19]\] when a HbA1C \>6.5 % was present and/or if a patient was treated with any antidiabetic drug or antidiabetic diet.

Laboratory analysis {#Sec5}
-------------------

At baseline, blood, plasma, serum and spot-urine samples were collected from each patient according to standard operation procedures, processed and shipped frozen to the central laboratory \[[@CR16]\]. HbA1C and hemoglobin were determined from thawed whole blood. HbA1C was measured using an International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) proven immunoassay (Cobas Integra 400 Plus, ROCHE Diagnostics, Switzerland). HbA1c results are reported in both NGSP (%) and IFCC (mmol/mol) units. According to recent recommendations, GFR was estimated using the CKD-EPI formula \[[@CR20]\].

Statistical methods {#Sec6}
-------------------

Baseline values of continuous variables are presented as mean ± standard deviation or median with 25^th^, 75^th^ percentiles. Values of categorical variables are presented as numbers and percentages. Spearman rank correlation coefficients were used to estimate correlation between continuous variables. Kruskal-Wallis tests were used to compare differences between independent groups of patients. In addition, Chi-Squared tests were used to evaluate associations between categorical variables. Effects of treatment on HbA1C levels were estimated by using stepwise logistic regression analysis with dependent variable "HbA1C below/above median of 7 %". This dichotomization was chosen based on median calculation (see below) and is in accordance with clinical relevance \[[@CR21], [@CR22]\] and evidence reporting differences in outcomes in randomized controlled trials \[[@CR10]\]. Using forward/backward stepwise selection as well as the inclusion of all covariates, models were adjusted for age, sex, body mass index (BMI), duration of CKD, physical activity, eGFR, hemoglobin, C-reactive protein, and antidiabetic medication (using dietary treatment alone as the reference category). A two-sided *p* value \<0.05 was considered significant. Statistical analyses were performed with SAS 9.2 (SAS Institute, Inc., Cary, NC).

Results {#Sec7}
=======

Baseline characteristics {#Sec8}
------------------------

Diabetes was diagnosed in 1842 of the 5217 GCKD patients and differences between those with and without diabetes have been published recently \[[@CR17]\]. In brief, patients with DM were significantly older than patients without DM (65 ± 8 vs. 58 ± 13 years, *p* \< 0.001), and the proportion of male patients was higher (67 vs. 56 %), *p* \< 0.001). Estimated GFR values were not significantly different (45 ± 16 mL/min/1.73 m^2^ in DM vs. 48 ± 17 mL/min/1.73 m^2^ in Non-DM, *p* = 0.07). The same was true for the urinary albumin/creatinine-ratio (UACR) (47 (9, 371) mg/g in DM vs. 54 (9, 397) mg/g in Non-DM, *p* = 0.45). In 213 patients with DM (12 %), eGFR was \>60 mL/min/1.73 m^2^. Only 107 patients had type 1 diabetes (mean age 57.8 ± 11.3 years, 67 (63 %) male, median eGFR 45 mL/min/1.73 m^2^ (36, 56), UACR 72 mg/g (8, 307). The self-reported duration of DM was ≥5 years in 1046 patients (57 %), 1--5 years in 236 (13 %), and \<1 year in 46 (2.5 %). In 514 patients the duration of DM was not known (28 %) and thus this factor was excluded from further statistical analysis. As main cause of CKD, the treating nephrologists listed diabetic nephropathy in 40 %, vascular nephropathy in 17 %, glomerulonephritis in 8 %, interstitial nephritis in 3 %, systemic disease in 3 %, and miscellaneous in 29 %. The rate of self-reported diabetic retinopathy was 20 % (*n* = 376).

The median HbA1C value of the study cohort was 7.0 % (6.8, 7.9), 53 mmol/mol (51, 63). Clinical data of patients with DM stratified according to their baseline HbA1C (equal or below vs above median) are shown in Table [1](#Tab1){ref-type="table"}. Most characteristics were similar between both groups, except that patients with an HbA1C ≤7.0 % were on average one year older, had slightly lower systolic blood pressure and BMI, lower UACR and CRP.Table 1Baseline data of 1842 patients with diabetes mellitus and CKD stratified by median HbA1C levels (7.0 %, 53 mmol/mol)HbA1C ≤ 7.0 % (53 mmol/mol) *n =* 897HbA1C \> 7.0 % (53 mmol/mol) *n* = 945Epidemiological data Age (years)65 ± 864 ± 8 Male, number (%)591 (65.9)637 (67.4) Systolic blood pressure (mm Hg)141 ± 22143 ± 21 Diastolic blood pressure (mm Hg)76 ± 1276 ± 12 BMI (kg/m^2^)32 ± 633 ± 6 Current smokers, number (%)127 (14.2)142 (15.0) Duration of CKD   ≥ 5 years369 (41.2)413 (43.7)  3 -- \< 5 years133 (14.8)162 (17.1)  1 -- \< 3 years207 (23.1)198 (21.0)   \< 1 year154 (17.2)130 (13.8) Physical activity  Less than once a week173 (19.3)201 (21.3)  1--2 times a week202 (22.6)221 (23.4)  3--5 times a week256 (28.6)236 (25.0)  More than 5 times a week251 (28.0)278 (29.5) CV disease, number (%) ^a^403 (44.9)463 (49.0)Laboratory data Creatinine (mg/dL)1.47 (1.23, 1.80)1.50 (1.27, 1.83) eGFR (mL/min/1.73 m^2^)44 (35, 55)44 (35, 54)  eGFR 0--29126 (14.1)125 (13.6)  eGFR 30--44322 (36.1)346 (37.6)  eGFR 45--59296 (33.2)301 (32.7)  eGFR ≥ 60148 (16.6)149 (16.2) Urinary albumin/creatinine-ratio (mg/gCrea)34 (7, 330)59 (10, 412)   \< 30420 (48.4)356 (38.7)  30--300216 (24.9)298 (32.4)   \> 300231 (26.6)266 (28.9) Hemoglobin (g/dL) ^a^13.4 (12.1, 14.5)13.6 (12.5, 14.5) HbA1C (%)6.6 (6.3, 6.8)7.9 (7.4, 8.6) HbA1C (mmol/mol)49 (45, 51)63 (57, 70) Serum albumin (g/L)38.6 (35.9, 40.6)38.1 (35.6, 40.5) CRP (mg/L)2.50 (1.24, 5.78)3.13 (1.47, 6.73)Calcium (mmol/L)2.27 (2.18, 2.35)2.28 (2.19, 2.36)Phosphate (mmol/L)1.11 (0.97, 1.25)1.09 (0.96, 1.23) Ca/Ph-Produkt (mmol^2^/L^2^)2.03 (1.79, 2.33)2.06 (1.79, 2.33) Total cholesterol (mg/dL) ^b^194.9 (167.4, 228.8)192.2 (161.2, 223.7) HDL (mg/dL) ^b^45.1 (37.4, 55.7)43.2 (35.8, 53.4) LDL (mg/dL) ^b^103.1 (82.9, 131.8)99.4 (75.3, 124.3) TG (mg/dl) ^c^180.9 (125.5, 259.8)197.1 (134.8, 279.4)Antidiabetic treatment strategies Dietary treatment alone292 (35.1)113 (13.5) Oral anti-diabetic drugs alone, *any*277 (33.3)149 (17.8) Oral anti-diabetic drugs plus insulin49 (5.9)92 (10.9) Insulin alone214 (25.7)485 (57.8)Values are reported as mean values ± standard deviation, medians (25^th^, 75^th^ percentile), or numbers (percentages), as appropiate. ^a^ The composite of cardiovascular disease includes all patients with one or more of the following: cardiac valve replacement, aortic aneurysm, coronary artery disease, cerebrovascular disease, peripheral artery disease^a^ For conversion into SI units (mmol/L): multiply with 0.62^b^ For conversion into SI units (mmol/L): multiply with 0.02586^c^ For conversion into SI units (mmol/L): multiply with 0.0114

Antidiabetic treatment {#Sec9}
----------------------

Roughly one quarter of the patients with DM were treated with an antidiabetic diet regimen only (24.2 %), or received oral antidiabetic drugs, but no insulin (25.5 %). The majority was treated with insulin only (41.8 %) and a small group was on insulin and oral antidiabetic agents (8.4 %) (Table [2](#Tab2){ref-type="table"}). Differences across groups of different therapeutic strategies including classes of oral antidiabetic drugs, alone or in combination, are presented in Table [2](#Tab2){ref-type="table"}. Patients who were treated with insulin alone were significantly younger but exhibited more advanced kidney disease with a lower eGFR and higher UACR. Moreover, they had the highest rate of pre-existing CVD; 88 out of the 699 patients in this group had type 1 diabetes. The opposite was true for patients being treated with oral antidiabetic drugs but not insulin. These patients had the highest eGFR, the lowest UACR, and the lowest rate of CVD. Their HbA1C was significantly lower (6.7 % (6.3, 7.3), 50 mmol/mol (45, 56)) as compared to the groups being treated with insulin, either alone (7.5 % (6.8, 8.4), 58 mmol/mol (51, 68)), or in the combination with oral antidiabetic drugs (7.5 % (6.8, 8.4), 58 mmol/mol (51, 68), *p* \< 0.0001 resp.). Almost one fifth of patients (18.8 %) received metformin alone or in any combination. In this group, eGFR was significantly higher as compared to patients not using metformin (53 (43, 62) vs. 42 (34, 52) mL/min/1.73 m^2^, *p* \< 0.0001). The lowest UACR (29 mg/g (6, 202)) was observed in those treated with DPP-4 inhibitors, alone or in combination. Only a small minority of 2.4 % (*n* = 45) were treated by GLP-1-agonists, either alone or in different combinations and were thus excluded from further statistical analysis.Table 2Patient characteristics in patients with diabetes mellitus and CKD across different antidiabetic treatment regimensDietary treatmentOral anti-diabetic drugs alone, *any*Oral anti-diabetic drugs plus insulinInsulin alone*P*-value ^a^Classes of oral antidiabetic drugs, alone or in combinationMetforminSulfonyl-ureasGlinidesDPP-4-inhibitorsNumber405426141699346265119191Percent24.225.58.441.818.814.46.510.4Age, *years*65 ± 865 ± 765 ± 764 ± 90.037764 ± 867 ± 666 ± 665 ± 7Male, *n (%)*270 (66.7)282 (66.2)89 (63.1)478 (68.4)0.64213 (61.6)175 (66.0)92 (77.3)129 (67.5)BMI, *kg/m* ^*2*^31 ± 632 ± 635 ± 632 ± 6\<0.000133 ± 633 ± 632 ± 634 ± 6Hemoglobin, *g/dL* ^*c*^13.6 (12.5, 14.8)13.5 (12.2, 14.5)13.6 (12.6, 14.5)13.3 (12.2, 14.4)0.083313.6 (12.3, 14.7)13.4 (12.5, 14.5)13.5 (12.5, 14.6)13.6 (12.5, 14.6)HbA1c, *%*6.7 (6.5, 7.1)6.7 (6.3, 7.3)7.5 (6.8, 8.4)7.5 (6.8, 8.4)\<0.00016.9 (6.4, 7.6)7.1 (6.5, 7.9)6.8 (6.5, 7.6)6.9 (6.4, 7.7)HbA1c, *mmol/mol*50 (48, 54)50 (45, 56)58 (51, 68)58 (51, 68)52 (46, 60)54 (48, 63)51 (48, 60)52 (46, 61)eGFR, *mL/min/1.73 m* ^*2*^44 (35, 55)48 (38, 58)46 (37, 56)41 (33, 51)\<0.000153 (43, 62)45 (36, 55)42 (33, 50)47 (36,56)UACR, *mg/gCrea*34 (8, 253)31 (8, 322)52 (9, 333)71 (11, 512)0.001138 (7, 369)50 (9, 329)45 (9, 371)29 (6, 202)CV disease, *n(%)* ^*b*^176 (43.5)169 (39.7)72 (51.1)382 (54.7)\<0.0001141 (40.7)120 (45.3)46 (38.7)88 (46.1)Duration of CKD  ≥ 5 years183 (45.3)152 (35.7)56 (39.7)324 (46.4)0.0021121 (34.9)99 (37.4)50 (42.0)68 (35.6) 3 -- \< 5 years65 (16.1)63 (14.8)23 (16.3)115 (16.5)50 (14.5)35 (13.2)20 (16.8)28 (14.7) 1 -- \< 3 years80 (19.8)108 (25.3)25 (17.7)152 (21.8)81 (23.4)69 (26.0)30 (25.2)47 (24.6)  \< 1 year63 (15.6)84 (19.7)22 (15.6)84 (12)66 (19.1)50 (18.9)17 (14.3)41 (21.4)Values are reported as numbers and percentages (based on all diabetic patients), mean values ± standard deviation, or medians (25^th^, 75^th^ percentile), as appropiateMissings (*n* = 171) resulted mostly from combinations that were used less frequently^a^ according to Kruskal-Walis test, analysis of variance, or Chi-Square test, as appropriate^b^ The composite of cardiovascular disease includes all patients with one or more of the following: cardiac valve replacement, aortic aneurysm, coronary artery disease, cerebrovascular disease, peripheral artery disease^c^ For conversion into SI units (mmol/L): multiply with 0.62

The eleven most commonly used antidiabetic regimes, based on individual drugs and the corresponding clinical data are presented in Table [3](#Tab3){ref-type="table"}. The metformin alone group showed the lowest HbA1C of 6.6 % (6.3, 7.1), 49 mmol/mol (45, 54) and the highest eGFR (56 ± 18 mL/min/1.73 m^2^) in combination with the lowest UACR (22 mg/gCrea (5, 247)). The highest levels of HbA1C were found in the small number of patients treated with insulin and sulfonylureas (7.8 % (7.0, 8.6), 62 mmol/mol (53, 70)) followed by patients who were treated with insulin and DPP-4 inhibitors having an HbA1C of 7.6 % (6.6, 8.7), 60 mmol/mol (47, 72). These two groups had the lowest average eGFR levels (42 ± 12 and 41 ± 12 mL/min/1.73 m^2^, respectively).Table 3Patient characteristics according to treatment with the 11 most commonly used antidiabetic treatment strategies in 1842 patients with diabetes mellitus and CKDInsulinDietary treatmentMetforminSulfonyl-ureasMetformin + InsulinGlinidesDPP-4 inhibitorsMetformin + Sulfonyl-ureasSulfonyl-ureas + InsulinMetformin + DPP-4 inhibitorsDPP-4\
inhibitors + InsulinN69940512312376594638383727Percent41.824.27.47.44.63.52.82.32.32.21.6Age, *years*64 ± 965 ± 864 ± 967 ± 664 ± 766 ± 665 ± 766 ± 566 ± 664 ± 865 ± 7Male gender, *n (%)*478 (68.4)270 (66.7)70 (56.9)80 (65.0)46 (60.5)45 (76.3)36 (78.3)29 (76.3)27 (71.1)22 (59.5)16 (59.3)BMI, *kg/m* ^*2*^32 ± 631 ± 633 ± 632 ± 535 ± 531 ± 534 ± 533 ± 634 ± 832 ± 536 ± 6Hemoglobin, *g/dL* ^b^13.2 (12.2, 14.4)13.6 (12.5, 14.8)13.7 (12.2, 5.0)13.4 (12.3, 14.5)13.7 (12.4, 14.4)13.5 (12.4, 14.5)13.1 (12.1, 14.3)13.1 (12.1, 14.4)13.7 (12.7, 14.7)14.1 (12.5, 15.1)13.5 (12.8, 14.1)HbA1c, *%* ^c^7.5 (6.8, 8.4)6.7 (6.5, 7.1)6.6 (6.3, 7.1)6.8 (6.3, 7.5)7.3 (6.8, 8.1)6.7 (6.3, 7.0)6.7 (6.3, 7.1)7.3 (6.6, 7.9)7.8 (7.0, 8.6)6.7 (6.4, 7.2)7.6 (6.6, 8.7)eGFR, *mL/min/1.73 m* ^*2*^43 ± 1546 ± 1756 ± 1845 ± 1255 ± 1742 ± 1045 ± 1352 ± 1642 ± 1253 ± 1741 ± 12UACR, *mg/gCrea*71 (11, 512)34 (8, 253)22 (7, 322)45 (8, 319)59 (7, 353)51 (8, 245)22 (5, 247)56 (14, 408)81 (12, 357)29 (6, 441)29 (14, 102)Duration of CKD, *n (%)*  ≥ 5 years324 (46.4)183 (45.3)38 (30.9)47 (38.2)32 (42.1)27 (45.8)16 (34.8)10 (26.3)14 (36.8)14 (37.8)10 (37) 3 -- \< 5 years115 (16.5)65 (16.1)19 (15.5)17 (13.8)13 (17.1)10 (17)9 (19.6)6 (15.8)4 (10.5)2 (5.4)6 (22.2) 1 -- \< 3 years152 (21.8)80 (19.8)29 (23.6)33 (26.8)11 (14.5)15 (25.4)9 (19.6)11 (29)10 (26.3)11 (29.7)4 (14.8)  \< 1 year84 (12)63 (15.6)27 (22)25 (20.3)11 (14.5)6 (10.2)11 (23.9)7 (18.4)5 (13.2)8 (21.6)6 (22.2)CV disease, *number (%)* ^*a*^382 (54.7)176 (43.5)38 (30.9)58 (47.2)38 (50)17 (28.8)17 (37)23 (60.5)16 (42.1)16 (43.2)18 (66.7)Values are reported as numbers and percentages (based on all diabetic patients), mean values ± standard deviation, or medians (25^th^, 75^th^ percentile), as appropriateMissings (*n* = 171) resulted mostly from combinations that were used less frequently^a^ The composite of cardiovascular disease includes all patients with one or more of the following: cardiac valve replacement, aortic aneurysm, coronary artery disease, cerebrovascular disease, peripheral artery disease^b^ For conversion of hemoglobin into SI units (mmol/L): multiply with 0.62^c^ For conversion of HbA1C into IFCC units (mmol/mol): (10.93 × HbA1C in %)-23.5

Glycaemic control and hemoglobin {#Sec10}
--------------------------------

The distribution of the HbA1C values is shown in Fig. [1](#Fig1){ref-type="fig"}. A great number of patients cluster around the median of 7.0 % (53 mmol/mol). Fourtyfive percent of the patients had HbA1C values within a range of 6.5--7.5 % (48--58 mmol/mol), 20 % below 6.5 %, and 35 % ≥7.5 %. There was a slight positive correlation of hemoglobin with HbA1C (*r* = 0.082, *p* = 0.001, Additional file [1](#MOESM1){ref-type="media"}: Figure S1) and eGFR (*r* = 0.247, *p* \< 0.0001, Additional file [2](#MOESM2){ref-type="media"}: Figure S2). No significant association of HbA1C with eGFR was found. Median HbA1c among the 107 patients with type 1 DM was 7.9 % (7.1, 8.8), 63 mmol/mol (54, 73), which was significantly higher compared with patients having type 2 DM (*n* = 1678, HbA1C 7.0 % (6.5, 7.8), 53 mmol/mol (48, 62), *p* \< 0.0001).Fig. 1Histogram of observed hemoglobin A1C (HbA1C) values in 1842 patients with diabetes mellitus and stage 3 CKD and/or overt proteinuria, for conversion of HbA1C into IFCC units (mmol/mol): (10.93 × HbA1C in %)-23.5

Factors associated with HbA1C {#Sec11}
-----------------------------

Factors associated with an HbA1C level above the median of 7.0 % (53 mmol/mol) were determined. For this analysis, clinical parameters (see method section) and different treatment strategies (oral and/or insulin treatment, dietary treatment as reference, see Table [2](#Tab2){ref-type="table"}) were included. Factors significantly associated with an HbA1C level \>7.0 % were higher body mass index (OR 1.038, *p* \< 0.0001) and higher hemoglobin (OR 1.112, *p* = 0.001, Table [4](#Tab4){ref-type="table"}). The use of oral antidiabetic drugs alone was not significantly associated with the probability of a median HbA1C \>7.0 % (Table [4](#Tab4){ref-type="table"}). Excluding the use of sulfonylureas did not increase the probability of an HbA1C \>7.0 % in those receiving oral anti-diabetic drugs only (OR 0.898, 95 % CI 0.625--1.291, *p* = 0.56). The use of insulin, either alone (OR 5.634, *p* \< 0.0001) or in the combination with oral antidiabetic drugs (OR 4.233, *p* \< 0.0001), was significantly associated with median HbA1C levels \>7.0 %. The entire model is presented in Additional file [3](#MOESM3){ref-type="media"}: Table S1.Table 4Correlates of median HbA1C levels \>7.0 % (53 mmol/mol) according to stepwise logistic regression analysis (final model)Indicators ^a,\ b^Regression coefficient ^a^Standard error ^a^Odds ratio ^a^95 % confidence interval ^a^*P*-value ^a^Body mass index (per 1 kg/m^2^ increase)0.03740.00911.0381.020--1.057\<0.0001Hemoglobin (per 1 g/dL increase) ^c^0.10600.03231.1121.044--1.1840.0010Antidiabetic treatment strategies ^b^ Oral anti-diabetic drugs alone, *any* (*n* = 426)0.21770.15661.2430.915--1.6900.16 Oral anti-diabetic drugs plus insulin (*n* = 141)1.44280.21594.2332.772--6.462\<0.0001 Insulin alone (*n* = 699)1.72880.14275.6344.260--7.452\<0.0001*N* = 266 observations were excluded from the analysis due to combinations that were used less frequently and missing values^a^ According to the final model; age, gender, BMI, duration of CKD, physical activity, eGFR, hemoglobin, CRP, and antidiabetic medication were used as variables in the initial model^b^ Dietary treatment was used as the reference category for any group of antidiabetic therapy^c^ For conversion into SI units (mmol/L): multiply with 0.62

We further analyzed the association of different treatment groups as outlined in Table [3](#Tab3){ref-type="table"} with HbA1C: The use of insulin, either alone or in combination with sulfonylureas, metformin, or DPP-4 inhibitors was significantly associated with median HbA1C levels \>7.0 % (OR between 3.373 and 7.726, *p* \< 0.0001, Additional file [4](#MOESM4){ref-type="media"}: Table S2). In contrast, the monotherapy with oral antidiabetic drugs such as metformin (OR 0.895, *p* = 0.0002), DPP-4 inhibitors (OR 0.864, *p* = 0.0117), or glinides (OR 0.898, *p* = 0.0069), and the combination of metformin with DPP-4 inhibitors (OR 0.970, *p* = 0.0417) was significantly associated with a decreased probability of median HbA1C levels \>7.0 %. Instead, treatment with sulfonylureas, either alone (OR 1.636, *p* = 0.31) or in the combination with metformin (OR 3.497, *p* = 0.07) or insulin (OR 7.726, *p* = 0.0002) was associated with an increased probability of median HbA1C levels \>7.0 % (Additional file [4](#MOESM4){ref-type="media"}: Table S2). The entire model is given in Additional file [5](#MOESM5){ref-type="media"}: Table S3.

Discussion {#Sec12}
==========

This study describes antidiabetic treatment reality in a large cohort of CKD patients with DM. All patients were under routine care of nephrologists and some of them were additionally seen by diabetologists, so that the data have to be interpreted as refecting specialist care.

A major finding of the analysis is that given the median HbA1C of 7.0 % (53 mmol/mol) \[[@CR21], [@CR22]\], the overall quality of DM control appears to be satisfactory in most of the patients despite the combination of CKD and DM. The treatment quality is comparable or even better than in large cohort studies of people with type 2 diabetes in Germany that have found mean HbA1C values of 7.0 and 7.2 % \[[@CR23], [@CR24]\]. German guidelines recommend an HbA1C between 6.5 and 7.5 % (48--58 mmol/mol) for all patients with DM irrespective of concomitant kidney disease \[[@CR22]\] and 45 % of our cohort met this criterium. The current U.S. National Kidney Foundation's Kidney Disease Outcome Initiative (K/DOQI) guidelines recommend a target HbA1C "*of \~7.0 % to prevent or delay progression of the microvascular complications of DM, including diabetic kidney disease*" \[[@CR21]\]. Thus, many of our patients were treated according to these guidelines. Other studies also confirm that good metabolic control can be achieved in patients with DM and CKD. In a Canadian population based study with 23,296 participants with DM and an eGFR of lower than 60 mL/min/1.73 m^2^, but not on dialysis, a median HbA1C level of 6.9 % was found \[[@CR25]\]. This study also reported an increase in the risk of mortality at HbA1C levels of \>8.0 and \<6.5 % \[[@CR25]\]. In this regard, it is noteworthy that 20 % of our cohort had an HbA1C below 6.5 % (48 mmol/mol), which might even suggest overtreatment or poor health status with an increased risk of hypoglycemia \[[@CR26]\]. On the other hand 24.7 % of patients with DM and CKD in the GCKD study had an HbA1C \>8.0 % (64 mmol/mol), indicating relevant heterogeneity and opportunities for improvement.

Interestingly the median dichotomization of our total cohort with a median HbA1C of 6.6 % (49 mmol/mol) in the lower group and a median of 7.9 % (63 mmol/mol) in the higher group corresponds to an intensive versus standard treatment approach when compared with the mean HbA1C values of the intensive (6.7 %, 50 mmol/mol) and standard (7.7 %, 61 mmol/mol) treatment groups in the ADVANCE, ACCORD, and the VADT trial \[[@CR10]\]. Although intensive compared with conventional glycaemic control did not result in significant differences for all-cause and CVD mortality, the risk of microvascular complications including kidney disease was lower in more intensively treated patients in these interventional trials \[[@CR27], [@CR28]\]. While our patients already had CKD at enrollment, it is possible that improved metabolic control retards the progression of already existing CKD. This may also reduce CVD morbidity and mortality in the long-term because any progression of CKD is associated with an exponential increase in CVD risk \[[@CR2], [@CR29]\].

CKD can be associated with anemia, which may limit the utility of HbA1c for diagnosing DM and assessing glycaemic control; HbA1C levels tend to be lower if renal anemia is present, due to a shortened life span of erythrocytes \[[@CR30]\]. Indeed, we found a slight but significant positive correlation between hemoglobin and HbA1C. However, in the majority of patients hemoglobin values were in the normal range and there was no difference in the mean hemoglobin concentrations between patients below and above the median HbA1C value. In addition, hemoglobin but not HbA1C was positively correlated with eGFR, confirming previous findings \[[@CR31]\].

A further important finding of our study is that antidiabetic treatment patterns differed from the general diabetes population and were overall highly variable. A total of slightly more than 50 % was treated with insulin-based therapies. In a German general type 2 diabetes population the portion of insulin-based therapies was 31 % which is 20 % lower than in the patients currently studied \[[@CR32]\]. More than 40 % of our patients were treated with insulin alone which is distinctly higher as in general diabetes cohorts including German cohorts in which only 10--20 % are treated with insulin monotherapy \[[@CR24], [@CR33], [@CR34]\]. Only one third of our patients was treated with oral glucose-lowering medication with or without insulin. In the German general diabetes population at least 60 to 70 % of the patients receive any oral antidiabetic medication \[[@CR23], [@CR24], [@CR32]\]. One quarter of our cohort was treated with oral antidiabetic agents alone comparing with up to 75 % in general diabetes cohorts \[[@CR24], [@CR35]\]. However, this portion is apparently lower in German diabetes cohorts; at about 40 to a maximum of 60 % \[[@CR23], [@CR24]\]. Different treatments were associated with different levels of metabolic control. The use of insulin, alone or in the combination with oral antidiabetic drugs, was accompanied by a 4 to nearly 6 times higher probability of having HbA1C values \>7.0 % (53 mmol/mol). Conversely, the use of oral glucose-lowering drugs alone, namely metformin, glinides, DPP-4 inhibitors, or the combination of metformin with DPP-4 inhibitors was not associated with such probability except sulfonylureas. The observational nature of the study precludes drawing conclusions on cause and effect when considering these differences in metabolic control in patients receiving different therapies and a number of factors may play a role. Thus it is not unlikely that patients whose diabetes was difficult to treat were switched to sulfonylureas or insulin, explaining at least in part higher HbA1C levels in these patients. On the other hand higher HbA1C targets may intentionally have been chosen in some patients. The K/DOQI guideline for CKD patients recommends that in patients "*with co-morbidities or limited life expectancy and risk of hypoglycemia*", target HbA1C should be extended above 7.0 % \[[@CR21]\]. While implementation of this recommendation could explain higher HbA1C levels in some patients, it appears unlikely that this applies to the majority of the insulin treated patients, given their younger age, no difference in eGFR, and only a slightly higher rate in prevalent CVD. On the other hand, their UACR was higher, the duration of CKD longer, and their physical activity was lower indicating more advanced diabetic disease. Furthermore, the K/DOQI guidelines recommend a HbA1C treatment target of \>7.0 % for patients at risk of hypoglycemia, "*including those treated with insulins or sulfonylureas and/or have advanced CKD*" \[[@CR21]\]. The amplified risk for hypoglycaemia in CKD is well documented, especially for patients treated with insulin or sulfonylureas \[[@CR5]\]. Indeed the mean HbA1C levels in patients receiving sulfonylureas in combination with metformin or insulin were higher than in many other groups, but this did not apply to those treated with sulfonylureas only. Conversely, the presence of a lower HbA1C in the orally treated patients (except those having sulfonylureas) is unlikely due to more frequent episodes of hypoglycaemia as metformin and DPP-4 inhibitors do not cause hypoglycaemia and the risk for hypoglycaemia is very low with the use of glinides, especially in CKD stages lower than stage G4 \[[@CR21]\]. Although patients difficult to treat with oral antidiabetic agents may have been switched to insulin, it is nevertheless noteworthy that a substantial proportion of patients was well controlled on oral agents only, indicating their potential value in the presence of CKD. Apart from the different antidiabetic therapies any increase in BMI was also significantly related to an HbA1C of \>7.0 % (53 mmol/mol) and may point towards a subgroup of patients whose DM is more difficult to treat due to increased insulin resistance.

Irrespective of the underlying reasons the association of insulin use with worse metabolic control has previously also been observed in other patient populations. A very large retrospective analysis compared patients with type 2 DM aged 50 years and older, in whom treatment was escalated from oral monotherapy to either a combination therapy of different oral antidiabetic drugs or to a regimen that included insulin. The use of insulin treatment was associated with an increase in HbA1C (8.3 % versus 7.7 % in the oral combination group), increased mortality (HR 1.49), and the increased likelihood of a first large-vessel disease event \[[@CR36]\]. In another retrospective study in type 2 DM patients from Germany, patients who were prescribed insulin or sulfonylurea, any combination of insulin with oral antidiabetic drugs, or the combination of sulfonylurea with metformin were least likely to achieve an intensive HbA1C target \[[@CR34]\].

Another confounding influence is based on the fact that drug licenses constrain the prescription depending on the level of kidney function. This is of particular relevance for metformin, which at the time of study enrollment and until recently was not approved in Germany for patients with an eGFR below 60 mL/min/1.73 m^2^ (now changed to below 45 ml/min/1.73 m^2^). Accordingly the eGFR was higher in those receiving metformin and the overall rate of metformin use in our cohort was \<20 %. This is distinctly lower as compared with current data from the U.S. National Health and Nutrition Examination Survey (NHANES) in which the rates of metformin use were 48.6 % and 57.4 % in eGFR ranges of 30 to 45 and \>45 to 60 mL/min/1.73 m^2^ \[[@CR37]\]. It should be noted that there is an ongoing debate whether the current thresholds for metformin use as suggested by guidelines may be too restrictive \[[@CR38]\]. The American Diabetes Association and the European Association for the Study of Diabetes stated that the England National Clinical Guideline for Management in Primary and Secondary Care from the National Institute for Health and Care Excellence (NICE) \[[@CR39]\] is more evidence based, generally allowing metformin use down to an eGFR of 30 mL/min/1.73 m^2^, with dose reduction advised at 45 mL/min/1.73 m^2^ \[[@CR38]--[@CR40]\]. This European guideline from 2009 may have prompted the German doctors as well, to prescribe metformin despite an eGFR of below 60 mL/min/1.73 m^2^.

Apart from its observational nature, there are further limitations of our study. We have no information on treatment duration and medication history, which would have allowed a better understanding on why patients were on particular therapies. In this regard there exists the possibility that patients on insulin are presumably the ones with more advanced disease with its attendant higher risk of complications and higher HbA1C. As a consequence, the treating physicians may have tended to use insulin in patients with a higher HbA1C and with complications when compared to patients with lower HbA1C. Thus, a causal association between the use of insulin and higher HbA1C and complications cannot be proven. Nevertheless, the cross-sectional nature of this baseline analysis prohibits conclusions on associations with outcomes. Although HbA1C still remains the cornerstone for the estimation of glycaemic control and as most clinical trials have used it \[[@CR41]\], it is sensitive to episodes of hypoglycaemia.

The strength of the study includes its size and the assessment of different types of antidiabetic medication. Medication information was directly obtained from the patient, possibly overcoming some of the uncertainties of implementation and validity of prescription orders in patients treated by more than one physician. HbA1C values were all determined in a central lab using identical methodology and interference from carbamylated hemoglobin could be excluded by using a specific immunoassay \[[@CR42]\].

Conclusions {#Sec13}
===========

Within a large cohort of referred patients with DM and CKD stage 3 and/or overt proteinuria, the overall treatment quality of DM was satisfactory, but relevant proportions of patients had HbA1C values below or above the recommended target range. The underlying treatment patterns differed from general diabetes cohorts with a remarkably high proportion of more than 50 % receiving insulin-based therapies which were associated with an increased probability of HbA1C levels \>7 % (53 mmol/mol). Future follow-up will reveal whether the level of control of DM in the presence of CKD and/or the choice of antidiabetic agent/s is associated with renal and CVD outcomes and differences in mortality.
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